D-Like Molecules as Treatments for HE, CTE
NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) — Kannalife Sciences, Inc. (“Kannalife”), a bio-pharmaceutical and phyto-medical company, is excited to announce that the Company will be featured in a Dateline NBC segment discussing how their research on cannabidiol (CBD)-like molecules could potentially change the landscape for various ailments including chronic traumatic encephalopathy (CTE) and the opioid epidemic.
The Kannalife-centric segment will air at 7:00pm EDT, during the Sunday, May 20th, episode of Dateline NBC. The segment will take an in-depth look into Kannalife Sciences and their groundbreaking research investigating whether the Company’s proprietary CBD-like molecules can help change the medical landscape and offer several new treatments for specific ailments.
“We are excited to be a part of this Dateline NBC special, dedicated to the therapeutic benefits of cannabinoids derived from the cannabis plant, cannabinoid-like molecules and how companies like Kannalife are working to conduct the necessary research to bring new drugs to market,” said Kannalife Sciences CEO Dean Petkanas. “This kind of exposure helps us communicate the health and wellness benefits of CBD and CBD-like molecules, as well as new potential treatments for CTE.”
A good portion of this news piece will focus on the problem of CTE, a degenerative neurological disease caused by repeated head trauma that can lead to symptoms like violent mood swings, depression and other cognitive difficulties. Currently, CTE can only be definitively diagnosed by direct tissue examination after death. Because there is not much known about this debilitating disease, treatment and prevention options are bleak.
Kannalife Sciences currently holds two licenses, one of them exclusive, with the National Institutes of Health (NIH) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”, to research Hepatic Encephalopathy (HE) and CTE.
Additionally, with over 20,000 deaths a year related to prescription opioids, Kannalife discusses the potential benefits of using cannabis as a replacement for opioids to not only help those suffering from addiction but as an alternative to opioids to treat chronic pain.
About Kannalife Sciences
Kannalife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer (“NIH-OTT”) for the Commercialization of U.S. Patent #6630507, “Cannabinoids as Antioxidants and Neuroprotectants”. Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat HE and CTE. HE and CTE are oxidative stress related diseases that affect the cognitive and behavioral functions, and the wellness of the brain.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
Public Relations Contact:
Chief Executive Officer